Banco Bilbao Vizcaya Argentaria S.A. Sells 3,472 Shares of Stryker Corporation $SYK

Banco Bilbao Vizcaya Argentaria S.A. lessened its position in Stryker Corporation (NYSE:SYK) by 5.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 62,198 shares of the medical technology company’s stock after selling 3,472 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Stryker were worth $22,985,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. California Public Employees Retirement System lifted its position in shares of Stryker by 16.0% in the third quarter. California Public Employees Retirement System now owns 848,186 shares of the medical technology company’s stock worth $313,549,000 after purchasing an additional 116,733 shares in the last quarter. Chilton Investment Co. Inc. grew its position in Stryker by 10.0% in the third quarter. Chilton Investment Co. Inc. now owns 3,363 shares of the medical technology company’s stock valued at $1,243,000 after purchasing an additional 306 shares in the last quarter. Bank of Nova Scotia increased its stake in Stryker by 175.3% in the 3rd quarter. Bank of Nova Scotia now owns 98,942 shares of the medical technology company’s stock valued at $36,576,000 after buying an additional 62,996 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in Stryker in the 3rd quarter valued at $567,000. Finally, Aquatic Capital Management LLC bought a new stake in Stryker during the 3rd quarter worth about $5,758,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 0.1%

Shares of SYK stock opened at $336.95 on Monday. Stryker Corporation has a 52-week low of $328.23 and a 52-week high of $404.87. The stock has a market cap of $128.95 billion, a price-to-earnings ratio of 40.11, a PEG ratio of 1.97 and a beta of 0.85. The firm’s 50-day moving average is $365.20 and its 200-day moving average is $367.34. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. The business had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.Stryker’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the company posted $4.01 earnings per share. Sell-side analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Stryker’s payout ratio is currently 41.90%.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Citi and some analysts view the pullback as a potential buying opportunity given Stryker’s fundamentals and upcoming catalysts — Citi put together a “90‑day catalyst watch” that sees upside despite the outage. Citi Sees Upside
• Positive Sentiment: Technicals may offer support: commentators note shares became oversold after the sell‑off and found support at a prior level, suggesting a possible technical bounce for traders. Stock Of The Day: Where Is The Bottom For Stryker?
• Neutral Sentiment: Stryker has publicly confirmed a cybersecurity incident and is investigating; the company is communicating updates as the situation evolves. Company Announcement
• Neutral Sentiment: Reporting shows the attack is causing real operational disruption to order processing, manufacturing and shipments — facts investors must watch to judge duration and revenue impact. Reuters: Disruption Report
• Negative Sentiment: Hackers claiming Iran linkage (group “Handala”) say the attack included destructive “wiper” activity and exfiltration of large volumes of data — allegations that raise the risk of extended downtime and regulatory/PR fallout. IBTimes: Hacker Claim
• Negative Sentiment: Operational paralysis from the incident has already pressured the stock, with multiple outlets reporting multi‑percent intraday declines as orders and shipments stall. Yahoo: Shares Fall
• Negative Sentiment: Social‑media driven selling amplified volatility — a viral Reddit thread and related headlines accelerated the recent drop, adding short‑term downside risk beyond fundamentals. 24/7 Wall St.: Reddit Impact

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

SYK has been the subject of a number of recent research reports. The Goldman Sachs Group set a $399.00 price objective on shares of Stryker in a research note on Friday, January 9th. Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 target price on the stock in a report on Tuesday, January 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a research report on Monday, December 22nd. BTIG Research raised their price target on Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $465.00 price target on shares of Stryker in a research report on Wednesday, March 4th. Fourteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $428.61.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.